BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on ...

Following a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) announced in March 2026, the Phase 3 program for BPL-003 in TRD remains on track for initiation in ...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway ...

AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its ...

AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more ...
Cricbuzz

BPL Auction: Mohammad Naim becomes most expensive player

Dasun Shanaka was the most expensive overseas player whereas Bangladesh veterans Mahmudullah and Mushfiqur initially went unsold before being bought ...

AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the publication of results from its ongoing Phase 2a clinical study ...
Global Trade Review (GTR)

BPL opens Japan office to tap credit insurance demand

Specialist insurance broker BPL has opened office in Tokyo to tap interest in credit and political risk insurance from ...